S100A9 and atherosclerosis: Indeed, plasma S100A8/S100A9 correlates with leukocyte counts and coronary artery disease (CAD) in type 1 diabetes (T1D) [60], suggesting that targeting of the S100A8/S100A9‐RAGE axis may reduce atherosclerosis and cardiovascular events in diabetic individuals with adequate glycaemic control.